Prima BioMed (NASDAQ:IMMP) Stock Price Passes Below 50-Day Moving Average – Here’s What Happened

Prima BioMed Ltd (NASDAQ:IMMP)’s share price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.44 and traded as low as $0.3925. Prima BioMed shares last traded at $0.4169, with a volume of 660,523 shares.

Analyst Upgrades and Downgrades

IMMP has been the subject of several analyst reports. Maxim Group raised shares of Prima BioMed from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. Wall Street Zen upgraded Prima BioMed to a “hold” rating in a research report on Saturday, April 18th. Robert W. Baird lowered Prima BioMed from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $7.00 to $1.00 in a research note on Friday, March 13th. Finally, Citizens Jmp cut Prima BioMed from an “outperform” rating to a “market perform” rating in a research report on Friday, March 13th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $5.50.

Prima BioMed Price Performance

The business’s 50 day moving average is $0.44 and its two-hundred day moving average is $1.52.

Institutional Trading of Prima BioMed

A hedge fund recently raised its position in Prima BioMed stock. Jane Street Group LLC lifted its stake in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 51,574 shares of the biotechnology company’s stock after acquiring an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.32% of the company’s stock.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.